CIK 0001645113
- Large accelerated filer
NovoCure Ltd
Sign in to watch- Ticker
- NVCR
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +44 1534756700
- Business address
- NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Jersey
- 3/A Insider 3/A
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President, CNS Cancers US sold 13,609 shares at an average $75.55 ($1,028,165)
- 4 Open-market sale Chief Growth Officer sold 21,421 shares at $76.16 ($1,631,411)
- 4 Open-market sale Chief Operating Officer sold 25,635 shares at $76.16 ($1,952,346)
- 4 Open-market sale Chief Financial Officer sold 5,505 shares at $76.16 ($419,257)
- 4 Open-market sale Chief Human Resources Officer sold 593 shares at $76.16 ($45,163)
- 4 Grant or award Chief Innovation Officer acquired 32,766 shares (grant or award)
- 4 Open-market sale Chief Human Resources Officer sold 281 shares at $75.28 ($21,153)
- 4 Open-market sale Chief Growth Officer sold 937 shares at $75.28 ($70,535)
- 4 Open-market sale Chief Operating Officer sold 1,213 shares at $75.28 ($91,312)
- 4 Open-market sale Chief Financial Officer sold 1,055 shares at $75.28 ($79,418)
- 4 Open-market sale President, CNS Cancers US sold 2,903 shares at an average $76.95 ($223,393)
- 4 Open-market sale President, CNS Cancers US sold 4,107 shares at an average $75.38 ($309,578)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President, CNS Cancers US sold 1,684 shares at $76.36 ($128,594)
- 4 Open-market sale Chief Growth Officer sold 1,923 shares at $76.36 ($146,845)
- 4 Grant or award Chief Innovation Officer acquired 12,992 shares (grant or award)
- 4 Grant or award General Counsel acquired 17,755 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 2,198 shares at $76.36 ($167,845)
Page 9 of 39 · 780 filings